hVIVO Group extends commercial offering following successful trial
hVIVO Group on Tuesday has successfully completed an respiratory syncytial virus (RSV) human challenge study conducted in adults aged 60-75 years at its specialist clinical facility in London.
Hvivo
16.50p
16:55 17/01/20
Pharmaceuticals & Biotechnology
22,025.61
11:45 24/04/24
The study extended the clinical development services company's commercial provision beyond an established RSV human challenge model in 18-60 year olds by demonstrating that older patients can safely take part in such clinical studies.
Volunteers stayed in hVIVO's human challenge clinical unit for a period of approximately two weeks after being inoculated with an RSV Memphis 37 Challenge virus strain, with volunteers monitored 24 hours a day for data concerning safety, infection rates, virology and symptoms collected before being safely discharged and followed up for 28 days post discharge.
Trevor Phillips, executive chairman of hVIVO, said: "These positive results mean we are now able to offer existing and new customers a model that targets a population that is particularly vulnerable to RSV and for use in vaccine or antiviral product development. The company's contract pipeline is experiencing a strong demand for RSV challenge study services and we anticipate this demand will continue reflective of the unmet medical need that companies are addressing."
hVIVO Group's shares were down 1.27% at 19.50p at 1041 BST.